Odyssey Therapeutics, Inc.’s Lock-Up Period Set To End Tomorrow (NASDAQ:ODTX)

Odyssey Therapeutics’ (NASDAQ:ODTX) lock-up period is set to end on Wednesday, November 4th. Odyssey Therapeutics had issued 15,500,000 shares in its IPO on May 8th. The total size of the offering was $279,000,000 based on an initial share price of $18.00. After the end of Odyssey Therapeutics’ lock-up period, restrictions preventing company insiders and major shareholders from selling shares in the company will be lifted.

Wall Street Analysts Forecast Growth

Several research firms recently commented on ODTX. HC Wainwright assumed coverage on shares of Odyssey Therapeutics in a research note on Thursday, August 27th. They issued a “buy” rating and a $44.00 price target on the stock. UBS Group initiated coverage on shares of Odyssey Therapeutics in a research report on Monday, October 12th. They issued a “buy” rating and a $27.00 price objective for the company. JPMorgan Chase & Co. upped their target price on shares of Odyssey Therapeutics from $26.00 to $29.00 and gave the stock an “overweight” rating in a research note on Friday, August 7th. Weiss Ratings started coverage on shares of Odyssey Therapeutics in a research report on Tuesday, August 11th. They set a “sell (d+)” rating on the stock. Finally, Raymond James Financial assumed coverage on shares of Odyssey Therapeutics in a research report on Thursday, October 8th. They set an “outperform” rating and a $42.00 target price on the stock. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $35.33.

Odyssey Therapeutics Stock Performance

ODTX opened at $19.53 on Tuesday. The company has a 50-day moving average of $21.66. Odyssey Therapeutics has a 1 year low of $15.10 and a 1 year high of $29.05.

Odyssey Therapeutics (NASDAQ:ODTX) last released its quarterly earnings results on Wednesday, August 5th. The company reported ($1.74) EPS for the quarter. Sell-side analysts predict that Odyssey Therapeutics will post -6.08 EPS for the current fiscal year.

Institutional Investors Weigh In On Odyssey Therapeutics

Large investors have recently bought and sold shares of the company. The Manufacturers Life Insurance Company acquired a new position in Odyssey Therapeutics in the 2nd quarter worth approximately $601,000. State Street Corp purchased a new position in Odyssey Therapeutics during the 2nd quarter worth approximately $1,477,000. Finally, Citadel Advisors LLC purchased a new position in Odyssey Therapeutics during the 2nd quarter worth approximately $4,162,000.

Odyssey Therapeutics Company Profile

Odyssey Therapeutics is a clinical-stage biotechnology company focused on discovering and developing precision medicines for immune-mediated diseases and cancer. The company combines computational biology, functional genomics, and experimental drug discovery to identify therapies directed at disease-driving biological pathways.

Its research programs are centered primarily on small-molecule medicines and other targeted approaches intended to modulate the immune system or address vulnerabilities in cancer cells.